Fig. 5: MVA-EbolaZ boosted EBOZ GP-specific antibody titers in participants with previous cAd3-Ebola vaccine exposure to similar magnitudes in Trial US and Trial UG. | npj Vaccines

Fig. 5: MVA-EbolaZ boosted EBOZ GP-specific antibody titers in participants with previous cAd3-Ebola vaccine exposure to similar magnitudes in Trial US and Trial UG.

From: Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

Fig. 5

Baseline (pre-cAd3)-subtracted antibody titers (y axis) in the weeks (x axis) following MVA-EbolaZ vaccination in the US (a) and UG (b) participants as assessed by Ebola Zaire GP ELISA. Data expressed as EC90 titers with 95% confidence intervals (CIs) indicated by error bars. The EBO High (short) group is the Trial US group with a prime-boost interval of 6–11 weeks.

Back to article page